The Activity of Crizotinib in Chemo-Refractory MET-Amplified Esophageal and Gastric Adenocarcinomas: Results from the AcSé-Crizotinib Program

BACKGROUND: The AcSé-crizotinib program provides extensive screening of crizotinib-targeted genomic alteration in several malignancies. We here report the results in patients with esogastric MET-amplified adenocarcinomas. OBJECTIVE: The objective of the study was to evaluate the efficacy and tolerab...

Descripción completa

Detalles Bibliográficos
Autores principales: Aparicio, Thomas, Cozic, Nathalie, de la Fouchardière, Christelle, Meriaux, Emeline, Plaza, Jérome, Mineur, Laurent, Guimbaud, Rosine, Samalin, Emmanuelle, Mary, Florence, Lecomte, Thierry, Gomez-Roca, Carlos, Haineaux, Paul-Arthur, Gratet, Alain, Selves, Jannick, Menu, Yves, Colignon, Nikias, Johnson, Laetitia, Legrand, Frédéric, Vassal, Gilles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105218/
https://www.ncbi.nlm.nih.gov/pubmed/33847874
http://dx.doi.org/10.1007/s11523-021-00811-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8105218/
https://www.ncbi.nlm.nih.gov/pubmed/33847874
http://dx.doi.org/10.1007/s11523-021-00811-8

Ejemplares similares